About two million people in Germany suffer from osteoarthritis of the joints. Because of the high incidence and the often unsatisfactory outcomes, the need for safe and effective orthopaedic treatment methods is very high. Under the pressure of the increasing annual number of joint operations for osteoarthritis (so-called total endoprosthesis, for short: TEP), as well as other surgical procedures such as arthroscopy, and the resulting cost burden on the healthcare system in Germany, there is a huge need for the expansion of existing as well as new conservative treatment methods.
In other words: For medical procedures for preserving the knee joint without requiring surgery. Enter ORTHOGEN Lab Services GmbH. The EOT®II syringe is used in the context of non-surgical treatment for osteoarthritis and joint problems. The patented process enables the attending physician to produce autologous conditioned serum (for short: ACS) using the EOT®II syringe in the laboratory.